Phase 2 data from PTC Therapeutics showed that the Novartis-partnered Huntington’s disease asset slowed progression by more ...
PTC Therapeutics, Inc. (NASDAQ:PTCT) ranks among the most profitable biotech stocks to buy now. On April 28, PTC Therapeutics ...
Earlier this week, PTC Therapeutics reported positive 24‑month interim data from the PIVOT-HD extension study, showing dose-dependent slowing of Huntington’s disease progression with votoplam and a ...
PTC Therapeutics Inc. PTCT shares are tumbling on Wednesday, after the company reported topline results from the 24-month interim analysis of its PIVOT-HD long-term extension study. According to a ...
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming ...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results